Clinical Trial Update: Pilot Study of IC14 (Atibuclimab), an Anti-CD14 Monoclonal Antibody, to Treat STEMI [Phase 1, Phase 2]

View source ↗

Summary

Pilot Phase 1/2 trial evaluating IC14 (Atibuclimab), an anti-CD14 monoclonal antibody, for treatment of ST-elevation myocardial infarction; the study is current…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• St-elevation Myocardial Infarction

Drugs mentioned

• IC14 (Atibuclimab) (Atibuclimab)

Snippet

Sponsor: Implicit Bioscience | Conditions: STEMI, STEMI (ST Elevation MI) | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING